☆ 4.7 Editorial Material

Circulating Cancer Cells and Their Clinical Applications

CLINICAL CHEMISTRY (2011)

Journal

CLINICAL CHEMISTRY

Volume 57, Issue 11, Pages 1478-1484

Publisher

AMER ASSOC CLINICAL CHEMISTRY

DOI: 10.1373/clinchem.2011.166678

Keywords

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

Significance

Scientific rigor

Rate this paper

Circulating Tumor Cells: Technologies and Their Clinical Potential in Cancer Metastasis

Jerry Xiao, Paula R. Pohlmann, Claudine Isaacs, Benjamin A. Weinberg, Aiwu R. He, Richard Schlegel, Seema Agarwal

Summary: CTCs play a crucial role in predicting patient survival and understanding the metastasis of cancer, with potential implications for disease management and treatment strategies.

BIOMEDICINES (2021)

Add to Collection

Review Medicine, Research & Experimental

Circulating tumor cells in gastric cancer: developments and clinical applications

Qian Deng, Bo Jiang, Haijiao Yan, Jun Wu, Zhenzhen Cao

Summary: Circulating tumor cells (CTCs) are shed from primary tumor or metastatic sites into the bloodstream and subsequently seed into distant tissues, serving as precursors of metastases. Gastric cancer (GC) is highly heterogeneous, making secondary pathological biopsy difficult and invasive examination harmful. In recent years, CTCs have shown great potential for tumor diagnosis, prognosis prediction, efficacy detection, and treatment guidance, although their role in GC remains limited. This review focuses on landmark studies demonstrating the technical approaches of CTCs monitoring in GC and highlights the clinical application of CTCs numbers and phenotypes in monitoring therapeutic efficacy and predicting patient prognosis through sequential blood analyses.

CLINICAL AND EXPERIMENTAL MEDICINE (2023)

Add to Collection

Review Oncology

Detection Methods and Clinical Applications of Circulating Tumor Cells in Breast Cancer

Hongyi Zhang, Xiaoyan Lin, Yuan Huang, Minghong Wang, Chunmei Cen, Shasha Tang, Marcia R. Dique, Lu Cai, Manuel A. Luis, Jillian Smollar, Yuan Wan, Fengfeng Cai

Summary: CTCs are cancer cells that can migrate through the circulatory system and cause metastasis. Liquid biopsy, especially that involving the collection of CTCs, is a non-invasive method to detect tumor cells in the circulatory system, allowing for earlier and easier detection than traditional tissue biopsies. It is crucial to develop accurate detection methods for further clinical applications due to the scarcity of CTCs in blood vessels.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Review Oncology

Biology, vulnerabilities and clinical applications of circulating tumour cells

Alexander Ring, Bich Doan Nguyen-Straeuli, Andreas Wicki, Nicola Aceto

Summary: In recent years, advancements in technology have allowed for the identification and study of rare circulating tumor cells (CTCs) from blood samples, leading to new research fields and potential clinical applications in liquid biopsies. Analysis of CTCs has revealed unique biological characteristics, such as the presence of CTC clusters and interactions with immune or stromal cells, impacting metastasis formation and providing insights for cancer vulnerabilities. This review discusses progress in understanding the biological features of CTCs and explores the potential for designing future clinical tools to improve cancer diagnosis and treatment.

NATURE REVIEWS CANCER (2023)

Add to Collection

Review Oncology

Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as a Liquid Biopsy Marker in Colorectal Cancer

Isabel Heidrich, Thaer S. A. Abdalla, Matthias Reeh, Klaus Pantel

Summary: Colorectal cancer is a common malignancy with high mortality rates, often due to tumor cells spreading through the blood. Liquid biopsy, which analyzes circulating tumor cells and cell-free DNA in the blood, offers new diagnostic and therapeutic opportunities for colorectal cancer patients. It has the potential to improve early detection, monitor disease progression, and guide personalized treatment strategies.

CANCERS (2021)

Add to Collection

Review Oncology

Clinical Applications of Circulating Tumour Cells and Circulating Tumour DNA in Non-Small Cell Lung Cancer-An Update

Joanna Kapeleris, Majid Ebrahimi Warkiani, Arutha Kulasinghe, Ian Vela, Liz Kenny, Rahul Ladwa, Kenneth O'Byrne, Chamindie Punyadeera

Summary: Despite efforts to improve early diagnosis of NSCLC, most patients still present with advanced stage disease. Liquid biopsy, as an emerging method, provides remarkable advantages in cancer diagnosis and prognosis, offering earlier monitoring and evaluation.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Review Oncology

Clinical applications of circulating tumor cells in hepatocellular carcinoma

Yinggang Hua, Jingqing Dong, Jinsong Hong, Bailin Wang, Yong Yan, Zhiming Li

Summary: Hepatocellular carcinoma is a highly malignant tumor with a poor prognosis. Circulating tumor cells, shed from the tumor, play a crucial role in the early diagnosis and monitoring of HCC patients.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Review Biotechnology & Applied Microbiology

Single-cell analysis of circulating tumour cells: enabling technologies and clinical applications

Payar Radfar, Hamidreza Aboulkheyr Es, Rob Salomon, Arutha Kulasinghe, Naveen Ramalingam, Ehsan Sarafraz-Yazdi, Jean Paul Thiery, Majid Ebrahimi Warkiani

Summary: Multimodal analysis of circulating tumor cells (CTCs) has the potential to provide significant insights for cancer research, aiding in understanding tumor development and metastasis mechanisms. Investigating CTCs and CTC clusters through single-cell analysis can provide crucial information for cancer treatment and management.

TRENDS IN BIOTECHNOLOGY (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Circulating Tumor Cells in Colorectal Cancer: Detection Systems and Clinical Utility

Jozsef Petrik, Donatella Verbanac, Marija Fabijanec, Andrea Hulina-Tomaskovic, Andrea Ceri, Anita Somborac-Bacura, Roberta Petlevski, Marija Grdic Rajkovic, Lada Rumora, Bozo Kruslin, Mario Stefanovic, Neven Ljubicic, Neven Barsic, Antonija Hanzek, Luka Bockor, Ivana Celap, Alma Demirovic, Karmela Barisic

Summary: This review provides an overview of the research conducted on circulating tumor cells (CTCs) with the aim of finding suitable detection systems and assessing the possibility of clinical applications in patients with colorectal cancer.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Clinical Relevance of Circulating Tumor Cells in Prostate Cancer Management

Wojciech A. Cieslikowski, Andrzej Antczak, Michal Nowicki, Maciej Zabel, Joanna Budna-Tukan

Summary: CTC enumeration shows promise in the management of prostate cancer, particularly in monitoring treatment outcomes. However, most data come from randomized studies of anticancer agents and may not directly translate into clinical practice. Further research is needed to understand the role of CTC in early-stage prostate cancer.

BIOMEDICINES (2021)

Add to Collection

Review Immunology

Engineered NK Cells Against Cancer and Their Potential Applications Beyond

Maria Karvouni, Marcos Vidal-Manrique, Andreas Lundqvist, Evren Alici

Summary: Cell therapy is an innovative approach that involves implanting, infusing, or grafting viable cells into a patient's body to treat damaged or malignant tissues. CAR-T cell therapy, which involves genetically modifying patient T cells to target tumor-specific antigens, has shown high objective response rates in clinical trials. However, T cell toxicity and the challenges of personalized therapy manufacturing limit their widespread use. Recent research suggests that NK cells offer a potentially safer and off-the-shelf treatment alternative.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Review Oncology

Detection and clinical significance of circulating tumor cells in colorectal cancer

Miao Jiang, Shuiling Jin, Jinming Han, Tong Li, Jianxiang Shi, Qian Zhong, Wen Li, Wenxue Tang, Qinqin Huang, Hong Zong

Summary: Liquid biopsy is a promising minimally invasive method for early colorectal cancer detection, sampling circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), microRNA (miRNA) and extracellular vesicles (EVs) to provide information on tumor dynamics.

BIOMARKER RESEARCH (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Exploring the Clinical Utility of Pancreatic Cancer Circulating Tumor Cells

Dannel Yeo, Althea Bastian, Heidi Strauss, Payal Saxena, Peter Grimison, John E. J. Rasko

Summary: This review summarizes the data on the utility of CTCs in PDAC and discusses the molecular profiling and culture methods of CTCs. CTCs have the potential to be used in screening, early diagnosis, prognostic assessment, and personalized management of PDAC.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Add to Collection

Article Oncology

Clinical Application of Circulating Tumor Cells and Circulating Endothelial Cells in Predicting Bladder Cancer Prognosis and Neoadjuvant Chemosensitivity

Xiao Yang, Jiancheng Lv, Zijian Zhou, Dexiang Feng, Rui Zhou, Baorui Yuan, Qikai Wu, Hao Yu, Jie Han, Qiang Cao, Min Gu, Pengchao Li, Haiwei Yang, Qiang Lu

Summary: CTCs and CECs play a significant role in early intervention, treatment decision-making, and prognosis prediction in bladder cancer.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Immunomodulatory Mechanisms of Mesenchymal Stem Cells and Their Potential Clinical Applications

Yutong Huang, Qiang Wu, Paul Kwong Hang Tam

Summary: Mesenchymal stem cells (MSCs) have multiple properties, including self-renewal, immunomodulation, and regenerative medicine, making them a potential therapeutic strategy for immune disorders.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Add to Collection

Editorial Material Oncology

Cancer Screening Companies Are Rapidly Proliferating: Are They Ready for Business?

Amaia Fernandez-Uriarte, Oscar D. Pons-Belda, Eleftherios P. Diamandis

Summary: Cancer screening has been an important field of research. Traditional biomarkers are not suitable for population screening. Circulating tumor DNA has emerged as a promising new marker for cancer, but there are still challenges and the accuracy of new screening tests needs further definition.

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2022)

Add to Collection

Article Biochemical Research Methods

Transcriptome profiling and proteomic validation reveals targets of the androgen receptor signaling in the BT-474 breast cancer cell line

Stella K. Vasiliou, Panagiota S. Filippou, Sergi Clotet-Freixas, Antoninus Soosaipillai, Ihor Batruch, Foivos Viktor Tsianos, Ana Konvalinka, Eleftherios P. Diamandis

Summary: This study found that AR regulates the metabolism of BT-474 cells by affecting the expression of a large number of genes and proteins. Further pathway analysis suggests that the androgen receptor acts as a tumor suppressor in BT-474 cells.

CLINICAL PROTEOMICS (2022)

Add to Collection

Letter Medicine, General & Internal

Convoluted molecular maze of neprilysin

Eleftherios P. Diamandis, Sok-Ja Janket, Harry A. Conte

DIAGNOSIS (2022)

Add to Collection

Letter Medical Laboratory Technology

A new method for early cancer detection based on platelet transcriptomics will have low positive predictive value

Eleftherios. P. P. Diamandis

CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2023)

Add to Collection

Article Medical Laboratory Technology

Multiplex proteomics using proximity extension assay for the identification of protein biomarkers predictive of acute graft-vs.-host disease in allogeneic hematopoietic cell transplantation

Ivan Pasic, Annie H. Ren, Ram Vasudevan Nampoothiri, Ioannis Prassas, Jeffrey H. Lipton, Jonas Mattsson, Eleftherios P. Diamandis, Fotios V. Michelis

Summary: Using a novel multiplex antibody-based proximity extension assay, researchers identified serum proteins, including SLAMF7, IL-1ra, BTN3A2, and DAB2, that may potentially serve as biomarkers for acute graft-vs.-host disease.

CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2023)

Add to Collection

Article Medical Laboratory Technology

Mucin 13 (MUC13) as a candidate biomarker for ovarian cancer detection: potential to complement CA125 in detecting non-serous subtypes

Annie H. Ren, Panagiota S. Filippou, Antoninus Soosaipillai, Lampros Dimitrakopoulos, Dimitrios Korbakis, Felix Leung, Vathany Kulasingam, Marcus Q. Bernardini, Eleftherios P. Diamandis

Summary: This study explored the potential of using MUC13 as an ovarian cancer biomarker to complement CA125. The results showed that MUC13 could be used to detect non-serous ovarian carcinoma and early-stage disease, in addition to CA125.

CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2023)

Add to Collection

Review Biochemistry & Molecular Biology

The roles of proteases in prostate cancer

Hannu Koistinen, Ruusu-Maaria Kovanen, Morley D. Hollenberg, Antoine Dufour, Evette S. Radisky, Ulf-Hakan Stenman, Jyotsna Batra, Judith Clements, John D. Hooper, Eleftherios Diamandis, Oliver Schilling, Antti Rannikko, Tuomas Mirtti

Summary: Since the proposition of the pro-invasive activity of proteolytic enzymes over 70 years ago, several roles for proteases in cancer progression have been established. About half of the 473 active human proteases are expressed in the prostate and many of the most well-characterized members of this enzyme family are regulated by androgens, hormones essential for development of prostate cancer. Most notably, several kallikrein-related peptidases, including KLK3 (prostate-specific antigen, PSA), the most well-known prostate cancer marker, and type II transmembrane serine proteases, such as TMPRSS2 and matriptase, have been extensively studied and found to promote prostate cancer progression. Recent findings also suggest a critical role for proteases in the development of advanced and aggressive castration-resistant prostate cancer (CRPC). Perhaps the most intriguing evidence for this role comes from studies showing that the protease-activated transmembrane proteins, Notch and CDCP1, are associated with the development of CRPC.

IUBMB LIFE (2023)

Add to Collection

Letter Medical Laboratory Technology

Please do not call it Theranos

Eleftherios P. Diamandis

CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2023)

Add to Collection

Article Oncology

Prognostic impact of kallikrein-related peptidase transcript levels in prostate cancer

Timo-Pekka K. Lehto, Ruusu-Maaria Kovanen, Susanna Lintula, Adrian Malen, Carolin Sturenberg, Andrew Erickson, Olli-Pekka Pulkka, Ulf-Hakan Stenman, Eleftherios P. Diamandis, Antti Rannikko, Tuomas Mirtti, Hannu Koistinen

Summary: This study aimed to investigate the mRNA levels and prognostic impact of all 15 human kallikrein-related peptidases (KLKs) and their targets, proteinase-activated receptors (PARs), in surgically treated prostate cancer (PCa). The results showed that the expression of KLK2, KLK3, KLK4, and KLK15 was closely associated with tumor aggressiveness and prognosis, suggesting their potential as prognostic biomarkers for PCa.

INTERNATIONAL JOURNAL OF CANCER (2023)

Add to Collection

Review Oncology

Detection and Molecular Characterization of Circulating Tumour Cells: Challenges for the Clinical Setting

Areti Strati, Athina Markou, Evgenia Kyriakopoulou, Evi Lianidou

Summary: Liquid biopsy, through the analysis of circulating tumour cells (CTCs) and tumour-derived material, has become a powerful tool in personalized medicine for monitoring cancer evolution and follow-up of cancer patients. CTC analysis has had a significant impact on cancer prognosis, minimal residual disease detection, treatment selection, and patient monitoring, with numerous clinical trials including a liquid biopsy arm. This review provides an overview of the clinical significance of CTCs in breast, prostate, and non-small-cell lung cancer, and highlights the potential of CTC single-cell analysis for understanding metastasis biology and the need for quality control and standardization of methodologies in this field.

CANCERS (2023)

Add to Collection

Article Oncology

Preoperative Mutational Analysis of Circulating Tumor Cells (CTCs) and Plasma-cfDNA Provides Complementary Information for Early Prediction of Relapse: A Pilot Study in Early-Stage Non-Small Cell Lung Cancer

A. N. Markou, D. Londra, D. Stergiopoulou, I. Vamvakaris, K. Potaris, I. S. Pateras, A. Kotsakis, V. Georgoulias, E. Lianidou

Summary: By comparing blood samples from early-stage NSCLC patients, it was found that simultaneous analysis of plasma-cfDNA and CTC-derived DNA can provide complementary molecular information and greater genomic diversity for cancer treatment and prognosis.

CANCERS (2023)

Add to Collection

Article Oncology

In Vivo Detection of Circulating Cancer-Associated Fibroblasts in Breast Tumor Mouse Xenograft: Impact of Tumor Stroma and Chemotherapy

Tao Lu, Lisa Oomens, Leon W. M. M. Terstappen, Jai Prakash

Summary: Cancer-associated fibroblasts (CAFs) are important drivers in the tumor microenvironment and facilitate the growth and survival of tumor cells, as well as metastasis formation. In this study, we aimed to study circulating CAFs (cCAFs) and circulating tumor cells (CTCs) in a preclinical breast tumor model in mice in order to understand the effect of chemotherapy on cCAFs and CTC formation. We found that tumors with CAFs grew faster than tumors without CAFs. Furthermore, chemotherapy may exacerbate the formation of cCAFs and CTCs, which may eventually support the formation of a metastasis niche in breast cancer.

CANCERS (2023)

Add to Collection

Letter Medical Laboratory Technology

Chatbot GPT can be grossly inaccurate

Eleftherios P. Diamandis

CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2023)

Add to Collection

Letter Medicine, General & Internal

Convicting a wrong molecule?

Sok-Ja Janket, Jukka H. Meurman, Eleftherios P. Diamandis

DIAGNOSIS (2023)

Add to Collection

Review Medicine, General & Internal

Tumor heterogeneity: how could we use it to achieve better clinical outcomes?

Arsani Yousef, Lucianna Ghobrial, Eleftherios P. Diamandis

Summary: Tumors vary in location, tissue type, and histological subtype. This review highlights current classification schemes for tumor heterogeneity and discusses its clinical significance. New molecular techniques offer affordable assessment of tumor heterogeneity, potentially revolutionizing cancer diagnosis and treatment. Standardized and reproducible assessment methods are needed to fully realize the benefits of tumor heterogeneity.

DIAGNOSIS (2023)

Add to Collection

No Data Available

Circulating Cancer Cells and Their Clinical Applications

Journal

Publisher

AMER ASSOC CLINICAL CHEMISTRY

Keywords

Categories

Ask authors/readers for more resources

Protocol

Reagent

Authors

I am an author on this paper

Reviews

Primary Rating

Secondary Ratings

Novelty

Significance

Scientific rigor

Rate this paper

Recommended

Export Citation

Share Paper